Efectividad del corticoide intratimpánico en el tratamiento de la enfermedad de Ménière. Estudio de cohortes.

  1. González-Zapatero, Jesús María 1
  2. Fernández-Nava, María José 1
  3. Ferreira-Cendón, Sofía 1
  4. González-Sánchez, Enrique 1
  5. Serradilla-López, José Manuel 1
  6. Batuecas-Caletrío, Ángel 1
  1. 1 Complejo Asistencial Universitario de Salamanca. Servicio de Otorrinolaringología y Cirugía de Cabeza y Cuello. Salamanca. España.
Revista:
Revista ORL

ISSN: 2444-7986,  2444-7986

Ano de publicación: 2022

Volume: 13

Número: 3

Páxinas: 193-201

Tipo: Artigo

DOI: 10.14201/ORL.27951 DIALNET GOOGLE SCHOLAR lock_openDialnet editor

Outras publicacións en: Revista ORL

Obxectivos de Desenvolvemento Sustentable

Resumo

Introduction and objective: Meniere´s disease (MD) is a chronic auditory pathology characterized by the presence of hearing loss, episodic dizziness and tinnitus. To value the hearing improvement and the reduction of vertiginous crises in patients with Meniere´s disease after the administration of intratympanic corticosteroids. Method: Retrospective cohort study of a sample of 55 patients diagnosed with definitive Meniere´s disease and treated with intratympanic corticosteroids (ITS). Results: Of the 39 patients who were treated with ITS for vertigo attacks, one month into the treatment, 27 had no attacks, 11 experienced a few (<5) and only 1 had several attacks (5-10). Six months after the first injection, 19 had no seizures, 13 reported a few, 5 had several, and 2 manifested numerous attacks (> 10). There were 16 patients treated with ITS for hearing loss and they reflected a mean hearing loss of 46.61 dB prior to the treatment. One month after the injection, the mean loss was 42.77 dB (1.84) and at six months it was 41.66 dB (2.95). Discussion: The audiometric benefit obtained is ?3 dB after ITS, other authors in their studies have obtained results similar to ours, of 3.3 dB and 2.3dB. A clear decrease in the number of vertiginous crises is reflected after the ITS, several authors reach our same conclusion. Conclusions: Our results show that intratympanic corticosteroids is an effective therapy for the control of vertiginous crises and hearing loss in patients with Meniere´s disease.

Referencias bibliográficas

  • Pérez H, López J, Morales C, Fernández NP. Enfermedad de Ménière: desde las ciencias básicas hacia la medicina clínica. Enferm Ménière desde las ciencias básicas hacia la Med clínica [Internet]. 2009;85–92. Available from: https://seorl.net/PDF/ponencias%20oficiales/2009%20Enfermedad%20de%20Meniere%20desde%20las%20ciencias%20b%C3%A1sicas%20hasta%20la%20medicina%20cl%C3%ADnica.pdf
  • Howard S Moskowitz, MD, PhD, Elizabeth A Dinces M. Enfermedad de Meniere: evaluación, diagnóstico y tratamiento. UpToDate. 2020;(Dm):1–29.
  • Morales Angulo C, Gómez Castellanos R, García Mantilla J, Bezos Capelastegui J, Carrera F. Epidemiología de la enfermedad de Menière en Cantabria. Acta Otorrinolaringol Esp. 2003;54:601–5.
  • López Escámez JA, Carey J, Chung WH, Goebel JA, Magnusson M, Mandalà M et al. Criterios diagnósticos de enfermedad de Ménière. Documento de consenso de la Bárány Society, la Japan Society for Equilibrium Research, la European Academy of Otology and Neurotology (EAONO). Acta Otorrinolaringol Esp. 2016;67(1):1-7.
  • Suarez Nieto C, Gil-Carcedo Garcia LM, Marco Algarra J, Medina JE, Ortega del Álamo P, Trinidad Pinedo J. Tratado de Otorrinolaringología y Cirugía de Cabeza y Cuello. In: Panamericana, editor. 2.a. 2007. p. 1841–62.
  • Attrache NA Al, Krstulovic C, Guillen VP, Pérez CM, Garrigues HP. Response over time of vertigo spells to intratympanic dexamethasone treatment in meniere’s disease patients. J Int Adv Otol. 2016;12(1):92–7.
  • Herraiz C, Plaza G, Aparicio JM, Gallego I, Marcos S, Ruiz C. Transtympanic steroids for ménière’s disease. Otol Neurotol. 2010;31(1):162–7.
  • Casani A Pietro, Piaggi P, Cerchiai N, Seccia V, Franceschini SS, Dallan I. Intratympanic treatment of intractable unilateral ménière disease: Gentamicin or dexamethasone? A randomized controlled trial. Otolaryngol - Head Neck Surg. 2012;146(3):430–7.
  • Lambert PR, Carey J, Mikulec AA, LeBel C. Intratympanic sustained-exposure dexamethasone thermosensitive gel for symptoms of ménière’s disease: Randomized phase 2b safety and efficacy trial. Otol Neurotol. 2016;37(10):1669–76.
  • Saeed BMN, Tawalbeh M, Al-Omari AF. Intratympanic dexamethasone in Meniere’s disease. Egypt J Ear, Nose, Throat Allied Sci. 2016;17(2):63–9.
  • Paragache G, Panda NK, Ragunathan M, Sridhara. Intratympanic dexamethasone application in Meniere’s disease - Is it superior to conventional therapy? Indian J Otolaryngol Head Neck Surg. 2005;57(1):21–3.
  • Silverstein H, Isaacson JE, Olds MJ, Todd Rowan P, Rosenberg S. Dexamethasone inner ear perfusion for the treatment of Meniere’s disease: A prospective, randomized, double-blind, crossover trial. Am J Otol. 1998;19:196–201.
  • Garduño-Anaya MA, De Toledo HC, Hinojosa-González R, Pane-Pianese C, Ríos-Castañeda LC. Dexamethasone inner ear perfusion by intratympanic injection in unilateral Ménière’s disease: A two-year prospective, placebo-controlled, double-blind, randomized trial. Otolaryngol - Head Neck Surg. 2005;133(2):285–94.
Fonte de datos: Dialnet